Audit 356651

FY End
2024-12-31
Total Expended
$6.57M
Findings
0
Programs
3
Year: 2024 Accepted: 2025-05-20
Auditor: Eisneramper LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.865 Child Health and Human Development Extramural Research $1.99M Yes 0
93.351 Research Infrastructure Programs $1.84M Yes 0
93.310 Trans-Nih Research Support $83,759 Yes 0

Contacts

Name Title Type
F696R1G6DN85 Thomas Malecki Auditee
2155577361 Jimmy Mo Auditor
No contacts on file

Notes to SEFA

Accounting Policies: The accompanying schedule of expenditures of federal awards (the "Schedule") includes the federal grant activity of National Disease Research Interchange ("NDRI") for the year ended December 31, 2024. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations ("CFR") Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards ("Uniform Guidance"). Because the Schedule presents only a selected portion of the operations of NDRI, it is not intended to, and does not, present the financial position, changes in net assets, or cash flows of NDRI. Expenditures reported on the schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: NDRI has elected not to use the ten percent de minimis indirect cost rate as allowed under Uniform Guidance. In November 2022, NDRI has been issued an indirect cost rate of 72% by the U.S. Department of Health and Human Services.